Member News

Advertising of Therapeutic Goods in Australia – Are your advertising campaigns compliant? – Stephens Lawyers & Consultants

Posted: 23 June 2022 Advertising compliance for therapeutic goods in Australia is complex, requiring one to remain up-to-date on a number of different advertising laws which are administered by different regulators.  This article provides a timely reminder that as…

First harvest at medicinal cannabis facility near Mildura in Victoria’s north-west

Posted: 16 June 2022 Key points: The first crop has been harvested from a medicinal cannabis facility built in a former fruit juice factory near Mildura Cann Group received approval to cultivate the crop at the $115 million…

2022 GSK Award for Research Excellence: nominations now open!

Posted: 10 June 2022 Nominations Close: 15 July 2022 The GSK Award for Research Excellence (ARE) is one of the most prestigious and longstanding awards available to the Australian medical research community. Among the previous recipients of the…

Immutep’s TACTI-002 trial meets primary endpoint in lung cancer

Posted: 6 June 2022 Immutep reports positive Overall Response Rate in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers  TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients…

Gilead Sciences awards $300,000 in funding for local research projects

Posted: 6 June 2022 Applications close: 22 August 2022 • Six successful applicants across Australia, including five women, awarded research grants as part of the Gilead Australia Fellowship: Grants Program 2022 • Awarded research projects span across the…

Committee for Melbourne – Welcome to our new CEO, Mark Melvin!

Posted: 2 June 2022. I would firstly like to say thank you to our members, stakeholders and secretariat for such a warm welcome. It is in an honour and a privilege to lead the Committee for Melbourne into…

Amplia Therapeutics (ASX:ATX) shows efficacy in model of lung fibrosis

Date posted: 2 June 2022 Amplia has released new data showing that in a head-to-head preclinical comparison, using a mouse model of idiopathic pulmonary fibrosis (IPF), AMP945 showed comparable efficacy to the current standard of care. The current…

Avatar Brokers Celebrates 20 Years

Posted: 30 May 2022 Avatar Brokers are proud to announce a significant milestone in the history of our company, with this month marking our 20th anniversary. Founded on May 29, 2002, Avatar Brokers began its operations after establishing…

Deadly partnership to bolster First Nations representation in medical research

Posted: 27 May 2022 WEHI has partnered with leading Indigenous not-for-profit, DeadlyScience, to foster the next generation of Aboriginal and Torres Strait Islander scientists, in the first partnership of its kind. At a glance WEHI partners with DeadlyScience to pave the…

EOI: COLLABORATIVE PROJECT PROPOSALS IN MEDICAL COUNTERMEASURES

Posted: 27 May 2022 Closing: 30 June 2022 DMTC SEEKS COLLABORATIVE PROJECT PROPOSALS IN MEDICAL COUNTERMEASURES All information about the EOI process and submission requirements can be found on our website. DMTC is an independent, not-for-profit company that…

Burnet Institute partners with Moderna to develop novel mRNA vaccines

Posted: 26 May 2022 Media Release: 18 May 2022 Burnet Institute is to partner with world-leading mRNA vaccine manufacturer Moderna, through their cutting-edge mRNA Access program, to develop novel mRNA vaccines for a range of emerging and neglected infectious…

Regulation of Cosmetics in Australia

Posted: 24 May 2022 Stephens Lawyers & Consultants Introduction The importation, manufacture, advertising and supply of cosmetics in Australia is highly regulated and complex.   Before a cosmetic product or range can be launched in the Australian market –…

Home

News & opinion

Member Directory

Events